Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab... Objectives To investigate early changes in tumour perfusion parameters by dynamic contrast-enhanced ultrasonography (D- CEUS) and to identify any correlation with survival and tumour response in patients with metastatic colorectal cancer (CRC) treated with bevacizumab (B). Methods Thirty-seven patients randomized to either chemotherapy (C) plus B or C alone were considered for this study. D- CEUS was performed at baseline and after the first treatment cycle (day 15). Four D-CEUS perfusion parameters were consid- ered: derived peak intensity (DPI), area under the curve (AUC), slope of wash-in (A) and time to peak intensity (TPI). Results In patients treated with C plus B, a ≥22.5%reductioninDPI, ≥20 % increase in TPI and ≥10 % reduction in AUC were correlated with higher progression-free survival in the C+B arm (p = 0.048, 0.024 and 0.010, respectively) but not in the C arm. None of the evaluated parameter modifications had a correlation with tumour response or overall survival. Conclusions D-CEUS could be useful for detecting and quantifying dynamic changes in tumour vascularity as early as 15 days after the start of B-based therapy. Although these changes may be predictive of progression-free survival, no correlation with response or overall survival was found. Key Points � http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Radiology Springer Journals

Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer

Download PDF
10 pages
Read Article

Loading next page...
 
/lp/springer_journal/dynamic-contrast-enhanced-ultrasonography-d-ceus-for-the-early-Us8K0lEJLL
Publisher
Springer Journals
Copyright
Copyright © 2018 by European Society of Radiology
Subject
Medicine & Public Health; Imaging / Radiology; Diagnostic Radiology; Interventional Radiology; Neuroradiology; Ultrasound; Internal Medicine
ISSN
0938-7994
eISSN
1432-1084
DOI
10.1007/s00330-017-5254-5
pmid
29417252
Publisher site
See Article on Publisher Site

Abstract

Objectives To investigate early changes in tumour perfusion parameters by dynamic contrast-enhanced ultrasonography (D- CEUS) and to identify any correlation with survival and tumour response in patients with metastatic colorectal cancer (CRC) treated with bevacizumab (B). Methods Thirty-seven patients randomized to either chemotherapy (C) plus B or C alone were considered for this study. D- CEUS was performed at baseline and after the first treatment cycle (day 15). Four D-CEUS perfusion parameters were consid- ered: derived peak intensity (DPI), area under the curve (AUC), slope of wash-in (A) and time to peak intensity (TPI). Results In patients treated with C plus B, a ≥22.5%reductioninDPI, ≥20 % increase in TPI and ≥10 % reduction in AUC were correlated with higher progression-free survival in the C+B arm (p = 0.048, 0.024 and 0.010, respectively) but not in the C arm. None of the evaluated parameter modifications had a correlation with tumour response or overall survival. Conclusions D-CEUS could be useful for detecting and quantifying dynamic changes in tumour vascularity as early as 15 days after the start of B-based therapy. Although these changes may be predictive of progression-free survival, no correlation with response or overall survival was found. Key Points �

Journal

European Radiology – Springer Journals

Published: Feb 7, 2018

References

  • Global cancer statistics, 2012
    Torre, LA; Bray, F; Siegel, R
  • ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
    Cutsem, E; Cervantes, A; Adam, R
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H; Fehrenbacher, L; Novotny, W
  • Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III Study
    Saltz, LBCS; Díaz-Rubio, E; Scheithauer, W
  • Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial
    Cunningham, D; Lang, I; Marcuello, E
  • Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound
    Zocco, MA; Garcovich, M; Lupascu, A
  • Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography
    Lavisse, S; Lejeune, P; Rouffiac, V
  • Functional and early evaluation of treatments in oncology: interest of ultrasonographic contrast agents
    Lassau, N; Lamuraglia, M; Leclere, J; Rouffiac, V
  • New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
    Eisenhauer, EA; Therasse, P; Bogaerts, J
  • Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib
    Baccala, A; Hedgepeth, R; Kaouk, J
  • Imaging of angiogenesis: clinical techniques and novel imaging methods
    Provenzale, JM
  • DCE-MRI in hepatocellular carcinoma-clinical and therapeutic image biomarker
    Chen, BB; Shih, TT
  • Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation
    Eschbach, RS; Fendler, WP; Kazmierczak, PM
  • CEUS: Where are we in 2015?
    Cantisani, V; Wilson, SR
  • Dynamic contrast-enhanced ultrasound parametric maps to evaluate intratumoral vascularization
    Pitre-Champagnat, S; Leguerney, I; Bosq, J
  • Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies
    Broillet, A; Hantson, J; Ruegg, C; Messager, T; Schneider, M
  • Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model
    Lucidarme, O; Kono, Y; Corbeil, J
  • Contrast-enhanced ultrasound with VEGFR2-targeted microbubbles for monitoring regorafenib therapy effects in experimental colorectal adenocarcinomas in rats with DCE-MRI and immunohistochemical validation
    Eschbach, RS; Clevert, DA; Hirner-Eppeneder, H
  • Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period
    Lassau, N; Lamuraglia, M; Koscielny, S
  • A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
    Fury, MG; Zahalsky, A; Wong, R
  • Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial
    Passardi, A; Nanni, O; Tassinari, D
  • Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver - update 2012: A WFUMB-EFSUMB initiative in cooperation with representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS
    Claudon, M; Dietrich, CF; Choi, BI
  • RECIST 1.1-Update and clarification: from the RECIST committee
    Schwartz, LH; Litiere, S; Vries, E
  • The EFSUMB Guidelines and recommendations on the clinical practice of contrast enhanced ultrasound (CEUS): update 2011 on non-hepatic applications
    Piscaglia, F; Nolsoe, C; Dietrich, CF
  • Standardization of dynamic contrast-enhanced ultrasound for the evaluation of antiangiogenic therapies: the French multicenter Support for Innovative and Expensive Techniques Study
    Lassau, N; Chapotot, L; Benatsou, B
  • Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography
    Lassau, N; Koscielny, S; Albiges, L
  • Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification-preliminary results
    Lassau, N; Koscielny, S; Chami, L
  • Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT
    Smith, AD; Lieber, ML; Shah, SN
  • Selection of an early biomarker for vascular normalization using dynamic contrast-enhanced ultrasonography to predict outcomes of metastatic patients treated with bevacizumab
    Lassau, N; Coiffier, B; Kind, M
  • Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study
    Lassau, N; Bonastre, J; Kind, M
  • 3D analysis is superior to 2D analysis for contrast-enhanced ultrasound in revealing vascularity in focal liver lesions - A retrospective analysis of 83 cases
    Dong, FJ; JF, X; Du, D
  • Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution
    Piscaglia, F; Cucchetti, A; Dietrich, CF; Salvatore, V